The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Hashim, Yassar M.
Sankpal, Narendra V.
Binder, Pratibha S.
Goedegebuure, S. Peter
Mach, Robert H.
Hawkins, William G.
Funding for this research was provided by:
National Cancer Institute (5R01CA16376402, P30 CA091842, T32 CA009621)
Text and Data Mining valid from 2017-01-17
Version of Record valid from 2017-01-17
27 August 2016
5 December 2016
17 January 2017